vs
Apellis Pharmaceuticals, Inc.（APLS）与NAVIENT CORP（NAVI）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是NAVIENT CORP的1.5倍（$199.9M vs $137.0M），NAVIENT CORP净利率更高（-5.0% vs -29.5%，领先24.4%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -38.3%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -30.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
纳文特公司是一家总部位于美国特拉华州威尔明顿的金融服务企业，前身是学生贷款服务商。公司于2014年由学生贷款机构萨利美拆分而来，目前在美国各地设有办事处，共有约4500名员工，2018年时曾承接全美四分之一的学生贷款业务，2024年被禁止承接联邦学生贷款业务。
APLS vs NAVI — 直观对比
营收规模更大
APLS
是对方的1.5倍
$137.0M
营收增速更快
APLS
高出32.4%
-38.3%
净利率更高
NAVI
高出24.4%
-29.5%
两年增速更快
APLS
近两年复合增速
-30.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $137.0M |
| 净利润 | $-59.0M | $-6.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | -5.9% |
| 净利率 | -29.5% | -5.0% |
| 营收同比 | -5.9% | -38.3% |
| 净利润同比 | -62.2% | -125.0% |
| 每股收益（稀释后） | $-0.40 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNAVI
| Q4 25 | $199.9M | $137.0M | ||
| Q3 25 | $458.6M | $161.0M | ||
| Q2 25 | $178.5M | $156.0M | ||
| Q1 25 | $166.8M | $156.0M | ||
| Q4 24 | $212.5M | $222.0M | ||
| Q3 24 | $196.8M | $396.0M | ||
| Q2 24 | $199.7M | $247.0M | ||
| Q1 24 | $172.3M | $287.0M |
净利润APLSNAVI
| Q4 25 | $-59.0M | $-6.0M | ||
| Q3 25 | $215.7M | $-86.0M | ||
| Q2 25 | $-42.2M | $14.0M | ||
| Q1 25 | $-92.2M | $-2.0M | ||
| Q4 24 | $-36.4M | $24.0M | ||
| Q3 24 | $-57.4M | $-2.0M | ||
| Q2 24 | $-37.7M | $36.0M | ||
| Q1 24 | $-66.4M | $73.0M |
营业利润率APLSNAVI
| Q4 25 | -25.6% | -5.9% | ||
| Q3 25 | 48.7% | -72.7% | ||
| Q2 25 | -18.6% | 11.5% | ||
| Q1 25 | -50.0% | -3.2% | ||
| Q4 24 | -12.3% | 11.7% | ||
| Q3 24 | -24.0% | 3.0% | ||
| Q2 24 | -14.7% | 19.4% | ||
| Q1 24 | -36.0% | 30.7% |
净利率APLSNAVI
| Q4 25 | -29.5% | -5.0% | ||
| Q3 25 | 47.0% | -53.4% | ||
| Q2 25 | -23.6% | 9.0% | ||
| Q1 25 | -55.3% | -1.3% | ||
| Q4 24 | -17.1% | 10.8% | ||
| Q3 24 | -29.2% | -0.5% | ||
| Q2 24 | -18.9% | 14.6% | ||
| Q1 24 | -38.5% | 25.4% |
每股收益（稀释后）APLSNAVI
| Q4 25 | $-0.40 | $-0.05 | ||
| Q3 25 | $1.67 | $-0.87 | ||
| Q2 25 | $-0.33 | $0.13 | ||
| Q1 25 | $-0.74 | $-0.02 | ||
| Q4 24 | $-0.30 | $0.24 | ||
| Q3 24 | $-0.46 | $-0.02 | ||
| Q2 24 | $-0.30 | $0.32 | ||
| Q1 24 | $-0.54 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $637.0M |
| 总债务越低越好 | — | $40.6B |
| 股东权益账面价值 | $370.1M | $2.4B |
| 总资产 | $1.1B | $48.7B |
| 负债/权益比越低杠杆越低 | — | 16.94× |
8季度趋势，按日历期对齐
现金及短期投资APLSNAVI
| Q4 25 | $466.2M | $637.0M | ||
| Q3 25 | $479.2M | $571.0M | ||
| Q2 25 | $370.0M | $712.0M | ||
| Q1 25 | $358.4M | $642.0M | ||
| Q4 24 | $411.3M | $722.0M | ||
| Q3 24 | $396.9M | $1.1B | ||
| Q2 24 | $360.1M | $1.1B | ||
| Q1 24 | $325.9M | $823.0M |
总债务APLSNAVI
| Q4 25 | — | $40.6B | ||
| Q3 25 | — | $41.4B | ||
| Q2 25 | — | $42.3B | ||
| Q1 25 | — | $42.9B | ||
| Q4 24 | — | $43.2B | ||
| Q3 24 | — | $44.7B | ||
| Q2 24 | — | $47.5B | ||
| Q1 24 | $93.1M | $50.8B |
股东权益APLSNAVI
| Q4 25 | $370.1M | $2.4B | ||
| Q3 25 | $401.2M | $2.4B | ||
| Q2 25 | $156.3M | $2.6B | ||
| Q1 25 | $164.2M | $2.6B | ||
| Q4 24 | $228.5M | $2.6B | ||
| Q3 24 | $237.1M | $2.7B | ||
| Q2 24 | $264.3M | $2.7B | ||
| Q1 24 | $266.7M | $2.8B |
总资产APLSNAVI
| Q4 25 | $1.1B | $48.7B | ||
| Q3 25 | $1.1B | $49.3B | ||
| Q2 25 | $821.4M | $50.2B | ||
| Q1 25 | $807.3M | $51.0B | ||
| Q4 24 | $885.1M | $51.8B | ||
| Q3 24 | $901.9M | $53.4B | ||
| Q2 24 | $904.5M | $56.6B | ||
| Q1 24 | $831.9M | $59.0B |
负债/权益比APLSNAVI
| Q4 25 | — | 16.94× | ||
| Q3 25 | — | 16.98× | ||
| Q2 25 | — | 16.52× | ||
| Q1 25 | — | 16.56× | ||
| Q4 24 | — | 16.35× | ||
| Q3 24 | — | 16.59× | ||
| Q2 24 | — | 17.30× | ||
| Q1 24 | 0.35× | 18.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $441.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSNAVI
| Q4 25 | $-14.2M | $441.0M | ||
| Q3 25 | $108.5M | $70.0M | ||
| Q2 25 | $4.4M | $126.0M | ||
| Q1 25 | $-53.4M | $71.0M | ||
| Q4 24 | $19.4M | $459.0M | ||
| Q3 24 | $34.1M | $-10.0M | ||
| Q2 24 | $-8.3M | $279.0M | ||
| Q1 24 | $-133.0M | $182.0M |
自由现金流APLSNAVI
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | — |
自由现金流率APLSNAVI
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | — |
资本支出强度APLSNAVI
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率APLSNAVI
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 9.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 19.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.75× | ||
| Q1 24 | — | 2.49× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NAVI
暂无分部数据
